Wegovy vs Mounjaro: Comparing the Top Weight Loss Injections

Tirzepatide produces more weight loss than semaglutide — and the gap is substantial. In the STEP-1 trial, Wegovy (semaglutide 2.4mg) achieved ~15% body weight loss over 68 weeks. In SURMOUNT-1, tirzepatide 15mg achieved ~21% weight loss over 72 weeks.

For a 250 lb patient, the practical difference:

• Wegovy: ~37.5 lbs lost
• Tirzepatide: ~52.5 lbs lost

That's an additional 15 lbs of weight loss with tirzepatide — roughly 40% more than semaglutide. The dual GLP-1/GIP mechanism produces greater appetite suppression and enhanced fat metabolism compared to GLP-1 alone.

Important caveat: The SURMOUNT-1 trial technically tested tirzepatide under the Zepbound brand for obesity — Mounjaro is the diabetes brand. When Mounjaro is prescribed off-label for weight loss, the results should be equivalent since it's the same molecule at the same doses. However, trial populations differed (SURMOUNT-1 enrolled patients without diabetes; STEP-1 included some with diabetes), which may slightly affect cross-trial comparisons.

Both medications produce transformative weight loss that far exceeds any prior pharmaceutical option. The question is whether the additional ~6% of body weight lost with tirzepatide justifies choosing it over Wegovy's other advantages.

This is the most important distinction in the GLP-1 space: Mounjaro and Zepbound are the exact same molecule (tirzepatide) from Eli Lilly, but with different FDA approvals and brand names.

• Mounjaro — FDA-approved for type 2 diabetes (May 2022)
• Zepbound — FDA-approved for chronic weight management (November 2023)

Why this matters: When people compare "Wegovy vs Mounjaro for weight loss," the technically correct comparison is Wegovy vs Zepbound — both are FDA-approved for weight management. Mounjaro is the diabetes brand, and using it for weight loss alone is considered off-label.

Insurance implications are significant:

• If you have type 2 diabetes, your doctor may prescribe Mounjaro, and insurance will cover it as a diabetes medication
• If your primary goal is weight loss without diabetes, you'll need Zepbound (or off-label Mounjaro), and insurance coverage for weight loss drugs varies dramatically
• Some insurers cover Zepbound for obesity but not Mounjaro off-label, or vice versa

Clinically identical: The medication inside the pen is the same. The dose ranges are the same. The side effects are the same. The only differences are the label, the price, and how insurance processes the claim. Ask your doctor which brand makes the most sense for your diagnosis and insurance situation.

Self-pay pricing dramatically favors tirzepatide:

• Wegovy injection: ~$1,349/mo list price
• Mounjaro via LillyDirect: $499/mo
• Zepbound via LillyDirect: Competitive pricing (varies by dose)

For self-pay patients, that's a $850/month savings — over $10,000/year — by choosing tirzepatide through LillyDirect. Eli Lilly's direct-to-consumer pricing model has fundamentally changed the GLP-1 cost landscape.

Wegovy has a cheaper alternative: The Wegovy pill launched at $149–299/month depending on dose. For patients who want semaglutide at a lower cost, the oral form narrows the price gap significantly — though it requires 30-minute fasting before meals.

With manufacturer savings cards, both drop to $25/month for commercially insured patients who qualify. At that price point, the decision becomes purely clinical rather than financial.

For uninsured or underinsured patients, the math strongly favors LillyDirect pricing. Novo Nordisk's list price for Wegovy injection remains one of the highest in the GLP-1 category. Unless you qualify for the savings card or have robust insurance coverage, Mounjaro or Zepbound through LillyDirect provides the same drug class at a fraction of the cost.

Both medications cause GI side effects — but Mounjaro's rates are consistently lower in clinical trials:

• Nausea: Wegovy ~44% vs Mounjaro ~25–33%
• Vomiting: Wegovy ~24% vs Mounjaro ~10–18%
• Diarrhea: Wegovy ~30% vs Mounjaro ~15–21%

Why does Mounjaro have fewer GI side effects? Two likely reasons:

1. The GIP receptor component may have a protective or moderating effect on GI symptoms that pure GLP-1 agonism triggers
2. Mounjaro's dose titration schedule is more gradual, giving the body more time to adapt at each dose level

Shared serious side effect warnings:

• Thyroid C-cell tumors: Both carry a boxed warning based on rodent studies. No confirmed causation in humans, but contraindicated in patients with personal/family history of medullary thyroid carcinoma
• Pancreatitis: Rare (<1%) for both — discontinue if severe abdominal pain occurs
• Gallbladder events: Rapid weight loss from either drug can trigger gallstones

Bottom line on tolerability: If GI side effects are a primary concern — especially nausea — Mounjaro offers a meaningful advantage. Patients who struggled with Wegovy's nausea often tolerate tirzepatide better.

The SELECT trial is Wegovy's most powerful differentiator. This landmark cardiovascular outcomes trial demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in overweight/obese adults with established cardiovascular disease — regardless of diabetes status.

This is a historic result:

• First anti-obesity medication ever proven to reduce heart attacks, strokes, and cardiovascular deaths
• The FDA added cardiovascular risk reduction to Wegovy's prescribing label
• Benefit was consistent across subgroups: age, sex, BMI, diabetes status, baseline CV risk
• NNT (number needed to treat) of approximately 67 over 3.3 years — meaningful at a population level

Mounjaro/tirzepatide's cardiovascular data is pending. The SURPASS-CVOT trial is evaluating tirzepatide's effects on cardiovascular outcomes but results have not yet been reported. Early signals from SURPASS trials show favorable changes in CV risk factors — blood pressure, lipids, inflammatory markers — but surrogate marker improvements don't guarantee event reduction.

For patients with established heart disease, prior heart attack/stroke, or high cardiovascular risk, Wegovy has a level of evidence that Mounjaro simply cannot match today. This is a critical clinical differentiator that may outweigh Mounjaro's advantages in weight loss and tolerability for the right patient population.

Both medications are widely available, but their paths to market and access models differ:

Wegovy:

• Available since June 2021 (injection)
• Severe supply shortages from 2022–2024 are largely resolved
• Wegovy pill launched December 2025, adding an oral option
• Available at major retail and specialty pharmacies

Mounjaro:

• Available since May 2022 for type 2 diabetes
• Zepbound (same molecule, weight loss brand) launched November 2023
• LillyDirect offers direct-to-consumer access with home delivery and competitive pricing
• Available at retail pharmacies and through the LillyDirect platform

LillyDirect is a game-changer for access. Eli Lilly's direct-to-consumer model bundles telehealth consultation, prescription, and home delivery — bypassing traditional pharmacy channels. For patients who face insurance barriers or high copays, this streamlined pathway has made tirzepatide more accessible than ever.

Novo Nordisk has responded by expanding Wegovy pill availability and maintaining competitive savings programs, but doesn't yet offer a direct-to-consumer platform comparable to LillyDirect.

Choose Wegovy if:

• FDA-approved weight loss indication matters — for insurance, documentation, and regulatory clarity
• You have cardiovascular disease or high CV risk — SELECT trial data provides uniquely proven heart benefits
• You want an oral option — the Wegovy pill offers a needle-free alternative
• You value an established safety track record — 5+ years of real-world data
• Your insurance covers Wegovy well and the savings card brings your copay to $25/mo

Choose Mounjaro/tirzepatide if:

• Maximum weight loss is your top priority — ~21% vs ~15% is clinically significant
• You prefer better GI tolerability — lower nausea rates make the experience more comfortable
• You're a self-pay patient — LillyDirect at $499/mo saves $850+/mo vs Wegovy injection
• You also have type 2 diabetes — Mounjaro's dual mechanism provides superior A1C reduction
• You don't mind off-label use for weight loss (or ask your doctor about Zepbound instead)

The most important thing is starting treatment. Both medications produce life-changing weight loss. Debating between them is far less important than beginning either one. Talk to your doctor about which fits your medical history, insurance, and goals.